Skip to main content
×
Home
    • Aa
    • Aa

Hormone replacement therapy for osteoporosis: clinical and pathophysiological aspects

  • JE Compston (a1)
Abstract

The pathogenetic role of oestrogen deficiency in osteoporosis was first postulated by Fuller Albright in 1941 and has subsequently become well established. Hormone replacement therapy prevents menopausal bone loss and is the only treatment which has convincingly been shown to reduce fracture risk at both the spine and hip. The mechanisms by which oestrogens affect bone, however, are poorly understood and many aspects of treatment remain ill-defined, in particular with respect to the duration of therapy and its long-term risks and benefits.

Copyright
Corresponding author
JE Compston, Department of Medicine, University of Cambridge Clinical School, Addenbrooke's Hospital, Cambridge CB2 2QQ, UK
References
Hide All
1Albright F, Smith PH, Richardson AM. Postmenopausal osteoporosis. JAMA 1941; 116: 2465–74.
2Compston JE. HRT and osteoporosis. Br Med Bull 1992; 48: 309–44.
3Melton LJ, Chrischilles EA, Cooper C, Lane AW, Riggs BL. Perspective. How many women have osteoporosis? J Bone Miner Res 1992; 7: 10051010.
4Kanis JA, Pitt FA. Epidemiology of osteoporosis. Bone 1992; 13 (suppl 1): 715.
5Schaadt O, Bohr H. Different trends of age-related diminution of bone mineral content in the lumbar spine, femoral neck and femoral shaft in women. Calcif Tissue Int 1988; 42: 7176.
6Riggs BL, Wahner HW, Melton LJ, Richelson LS, Judd HL, Offord KP. Rates of bone loss in the appendicular and axial skeletons of women. Evidence of substantial vertebral bone loss before menopause. J Clin Invest 1986; 77: 1487–91.
7Rodin A, Murby B, Smith MA et al. Premenopausal bone loss in the lumbar spine and neck of femur: a study of 225 Caucasian women. Bone 1990; 11: 15.
8Cann CE, Genant HK, Kolbo FO, Ettinger B. Quantitative computed tomography for prediction of vertebral fracture risk. Bone 1985; 6: 17.
9Hui SL, Slemenda CW, Johnston CC, Appledorn CR. Effects of age and menopause on vertebral bone density. Bone Miner 1987; 2:141–46.
10Elders PJM, Netelenbos JC, Lips P, van Ginkel FC, van der Stelt PF. Accelerated vertebral bone loss in relation to the menopause: a cross-sectional study on lumbar bone density in 286 women of 46–55 years of age. Bone Miner 1988; 5: 1119.
11Nilas L, Christiansen C. Rates of bone loss in normal women: evidence of accelerated trabecular bone loss after the menopause. Eur J Clin Invest 1988; 18: 529–34.
12Genant HK, Cann CE, Ettinger B, Gilbert SG. Quantitative computed tomography of vertebral spongiosa: a sensitive method for detecting early bone loss after oophorectomy. Ann Intern Med 1982; 97: 699705.
13Mazess RB, On ageing and bone loss. Clin Orthop 1982; 165: 239–52.
14Riggs BL, Wahner HW, Dunn WL, Mazess RB, Offord KP, Melton LJ. Differential changes in bone mineral density of the appendicular skeleton with ageing: relationship to spinal osteoporosis. J Clin Invest 1987; 80: 258–62.
15Christiansen C, Riis BJ, Rodbro P. Prediction of rapid bone loss in postmenopausal women. Lancet 1987; i: 1105–108.
16Hui SL, Slemenda CW, Johnston CC. The contribution of bone loss to postmenopausal osteoporosis. Osteoporos Int 1990; 1: 3034.
17Rigotti NA, Nussbaum SR, Herzog DB, Neer RM. Osteoporosis in women with anorexia nervosa. N Engl J Med 1984; 311: 1601–606.
18Shore RM, Chesney RW, Mazess RB, Rose PG, Bergman GJ. Skeletal demineralisation in Turner's syndrome. Calcif Tissue Int 1982; 34: 519–22.
19Klibanski A, Greenspan SL. Increase in bone mass after treatment of hyperprolactinaemic amenorrhoea. N Engl J Med 1986; 315: 542–46.
20Drinkwater BL, Nilson K, Chestnut CH, Bremmer WJ, Shainholtz S, Southworth MB. Bone mineral content of amenorrhoeic and eumenorrhoeic athletes. N Engl J Med 1984; 311: 277–81.
21Matta WH, Shaw RW, Hesp R, Evans R. Reversible trabecular bone density loss following induced hypo-oestrogenism with the GnRH analogue buserelin in premenopausal women. Clin Endocrinol (Oxf) 1988; 29: 4551.
22Alderman BW, Weiss NS, Daling JR, Ure CL, Ballard JH. Reproductive history and postmenopausal risk of hip and forearm fracture. Am J Epidemiol 1986; 124: 262–67.
23Murphy S, Khaw K-T, Compston JE. Lack of relationship between hip and spine bone mineral density and oral contraceptive use. Eur J Clin Invest 1993; 23: 108–11.
24Lindsay R, Hart DM, Forrest C, Baird C. Prevention of spinal osteoporosis in oophorectomised women. Lancet 1980; ii: 1151–53.
25Nactigall LE, Nachtigall RH, Nachtigall RD, Beckman EM. Estrogen replacement therapy 1: a 10-year prospective study in the relationship to osteoporosis. Obstet Gynecol 1979; 53: 277–81.
26Christiansen C, Christensen MS, McNair PL, Hagen C, Stocklund KE, Transbol I. Prevention of early postmenopausal bone loss: conducted 2-year study in 315 normal females. Eur J Clin Invest 1980; 10: 273–79.
27Ettinger B, Genant HK, Cann CE. Long-term oestrogen replacement therapy prevents bone loss and fractures. Ann Intern Med 1985; 102: 319–24.
28Christiansen C, Riis BJ. 17β-estradiol and continuous norethisterone: a unique treatment for established osteoporosis in elderly women. J Clin Endocrinol Metab 1990; 71: 836–41.
29Stevenson JC, Cust MP, Gangar KF, Hillard TC, Lees B, Whitehead MI. Effects of transdermal versus oral hormone replacement therapy on bone density in spine and proximal femur in postmenopausal women. Lancet 1990; 335: 265–69.
30Gallagher JC, Kable WT, Goldgar D. Effect of progestin therapy on cortical and trabecular bone: comparison with estrogen. Am J Med 1991; 90: 171–78.
31Hutchinson A, Polansky SM, Feinstein AR. Post-menopausal estrogens protect against fractures of the hip and distal radius: a case control study. Lancet 1979; ii: 705709.
32Weiss NS, Ure CL, Ballard JH, Williams AR, Daling JR. Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogens. N Engl J Med 1980; 303: 1195–98.
33Paganini-Hill A, Ross RK, Gerkins VR, Henderson BE, Arthur M, Mack TM. Menopausal estrogen therapy and hip fractures. Ann Intern Med 1981; 95: 2831.
34Kiel DP, Felson DT, Anderson JJ, Wilson PWF, Moskowitz MA. Hip fracture and the use of estrogens in postmenopausal women: the Framingham study. N Engl J Med 1987; 317: 1169–74.
35Naessen T, Persson I, Adami H-O, Bergstrom R, Bergkvist L. Hormone replacement therapy and risk for first hip fracture. Ann Intern Med 1990; 113: 95103.
36Riggs BL, Seeman E, Hodgson SF, Taves DR, O'Fallon WM. Effect of the fluoride/calcium regimen on vertebral fracture occurrence in postmenopausal osteoporosis. N Engl J Med 1982; 306: 446–50.
37Lindsay R, Hart DM, MacLean A, Clark AC, Kraszewski A, Garwood J. Bone response to termination of oestrogen treatment. Lancet 1978; i: 1325–27.
38Christiansen C, Christensen MS, Transbol I. Bone mass in postmenopausal women after withdrawal of oestrogen/gestagen therapy. Lancet 1981; i: 459–61.
39Felson DT, Zhang Y, Hannan MT, Kiel DP, Wilson PWF, Anderson JJ. The effect of postmenopausal estrogen therapy on bone density in elderly women. N Engl J Med 1993; 329: 1141–46.
40Hayes WC, Gerhart TN. Biomechanics of bone: applications for assessment of bone strength. In: Peck WA ed. Bone and mineral research Volume 3, Amsterdam: Elsevier, 1985: 259–94.
41Wasnich RD, Ross PD, Heilbrun LK, Vogel JM. Prediction of postmenopausal fracture risk with bone mineral measurements. Am J Obstet Gynecol 1985; 153: 745–51.
42Hui SL, Slemenda CW, Johnston CC. Age and bone mass as predictors of fracture in a prospective study. J Clin Invest 1988; 81: 1804–809.
43Gärdsell P, Johnell O, Nilsson B. Predicting fractures in women by using forearm bone densitometry. Calcif Tissue Int 1989; 44: 235–42.
44Cummings SR, Black DM, Nevitt MC et al. Bone density at various sites for prediction of hip fractures. Lancet 1993; 341: 7275.
45Faulkner KG, Cummings SR, Glüer CC, Palermo L, Black D, Genant HK. Simple measurement of femoral geometry predicts hip fracture. J Bone Miner Res 1993; 8: 1211–17.
46Ross PD, Davis JW, Epstein RS, Wasnich RD. Pre-existing fractures and bone mass predict vertebral fracture incidence in women. Ann Intern Med 1991; 114: 919–23.
47Slemenda CW, Hui SL, Longcope C, Wellman H, Johnston CC. Predictors of bone mass in perimenopausal women. A prospective study of clinical data using photon absorptiometry. Ann Intern Med 1990; 112: 96101.
48Grady D, Rubin SM, Petitti DB et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992; 117: 1016–37.
49Bergkvist L, Adami HO, Persson I, Hoover R, Schairer C. The risk of breast cancer after estrogen and estrogen-progestin replacement. N Engl J Med 1989; 321: 293–97.
50Colditz GA, Stampfer MJ, Willett WC, Hennekens CH, Rosner B, Speizer FE. Prospective study of estrogen replacement therapy and risk of breast cancer in postmenopausal women. JAMA 1990; 264: 2648–53.
51Bush TL, Barrett-Connor E, Cowan LD et al. Cardiovascular mortality and non-contraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-Up Study. Circulation 1987; 75: 1102–109.
52Barrett-Connor E, Bush TL. Estrogen and coronary heart disease in women. JAMA 1991; 265: 1861–67.
53Wolf PH, Madans JH, Finucane FF, Higgins M, Kleinman JC. Reduction of cardiovascular disease-related mortality among postmenopausal women who use hormones: evidence from a national cohort. Am J Obstet Gynecol 1991; 164: 489–94.
54Nabulsi AA, Folsom AR, White A et al. Association of hormone replacement therapy with various cardiovascular risk factors in postmenopausal women. N Engl J Med 1993; 328: 1069–75.
55Falkeborn M, Persson I, Adami H-O et al. The risk of acute myocardial infarction after oestrogen and oestrogen-progestogen replacement. Br J Obstet Gynaecol 1992; 99: 821–28.
56Falkeborn M, Persson I, Terént A, Adami H-O, Lithell H, Bergström R. Hormone replacement therapy and the risk of stroke. Arch Intern Med 1993; 153: 1201–209.
57Parfitt AM. The cellular basis of bone remodelling. The quantum concept re-examined in light of recent advances in cell biology of bone. Calcif Tissue Int 1984; 36 (suppl): S37S45.
58Lanyon LE. The success and failure of the adaptive response to functional load-bearing in averting vertebral fracture. Bone 1992; 13 (suppl 2): S17S21.
59Scheven BAA, Visser JWM, Nijweide PJ. In vitro osteoclast generation from different bone marrow fractions, including a highly enriched haematopoietic stem cell population. Nature 1986; 321: 7981.
60Horton MA, Davies J. Perspectives: adhesion receptors in bone. J Bone Miner Res 1989; 4: 803807.
61Baron R, Vignery A, Horowitz M. Lymphocytes, macrophages and the regulation of bone remodelling. In: Peck WA ed. Bone and mineral research, Volume 2. Amsterdam: Elsevier, 1984: 175245.
62Owen ME. Lineage of osteogenic cells and their relationship to the stromal system. In: Peck WA ed. Bone and mineral research, Volume 3. Amsterdam: Elsevier, 1985: 125.
63Compston JE, Croucher PI. Histomorphometric assessment of trabecular bone remodelling in osteoporosis. Bone Miner 1991; 14: 91102.
64Frost HM. Tetracycline-based histological analysis of bone remodelling. Calcif Tissue Int 1969; 3: 211–37.
65Eriksen EF. Normal and pathological remodelling of human trabecular bone: three dimensional reconstruction of the remodelling sequence in normals and in metabolic bone disease. Endocr Rev 1986; 7: 379408.
66Garrahan NJ, Croucher PI, Compston JE. A computerised technique for the quantitative assessment of resorption cavities in trabecular bone. Bone 1990; 11: 241–46.
67Cohen-Solal ME, Shih M-S, Lundy MW, Parfitt AM. A new method for measuring cancellous bone erosion depth: application to the cellular mechanisms of bone loss in postmenopausal osteoporosis. J Bone Miner Res 1991; 6:1331–38.
68Russell RGG. The physiological regulation of bone metabolism. In: Ring EFJ, Evans WD, Dixon AS eds. Osteoporosis and bone mineral measurement. York, England: IPSM, 1989: 147–76.
69MacDonald BR, Gowen M. Cytokines and bone. Br J Rheumatol 1992; 31: 149–55.
70Gallagher JC, Godgar D. Treatment of postmenopausal osteoporosis with high doses of synthetic calcitriol. Ann Intern Med 1990; 113: 649–55.
71Lukert BP, Raisz LG. Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann Intern Med 1990; 112: 352–64.
72Reeve J, Meunier PJ, Parsons JA. Anabolic effect of human parathyroid fragment on trabecular bone in involutional osteoporosis: a multicentre trial. Br Med J 1980; 280: 1340–44.
73O'Halloran DJ, Tsatsoulis A, Whitehouse RW, Holmes SJ, Adams JE, Shalet SM. Increased bone density after recombinant human growth hormone (GH) therapy in adults with isolated growth hormone deficiency. J Clin Endocrinol Metab 1993; 76: 1344–48.
74Allain TJ, McGregor AM. Thyroid hormones and bone. J Endocrinol 1993; 139: 918.
75Felix R, Cecchini MG, Fleisch H. Macrophage colony stimulating factor restores in vivo bone resorption in the op/op osteopetrotic mouse. Endocrinology 1990; 127: 2592–94.
76Heaney RP, Recker RR, Saville PD. Menopausal changes in calcium balance performance. J Lab Clin Med 1978; 92: 953–63.
77Nordin BEC, Need AG, Morris HA, Horowitz M, Robertson WG. Evidence for a renal calcium leak in postmenopausal women. J Clin Endocrinol Metab 1991; 72: 401407.
78Stepan JJ, Pospichal J, Presl J, Pacovsky V. Bone loss and biochemical indices of bone remodelling in surgically induced postmenopausal women. Bone 1987; 8: 279–84.
79Wronski TJ, Lowry PL, Walsh CC, Ignazewski LA. Skeletal alterations in ovariectomised rats. Calcif Tissue Int 1985; 37: 324–28.
80Vedi S, Compston JE, Webb A, Tighe JR. Histomorphometric analysis of dynamic parameters of trabecular bone formation in the iliac crest of normal British subjects. Metab Bone Dis Relat Res 1983; 5: 6974.
81Eastell R, Delmas PD, Hodgson SF, Eriksen EF, Mann KG, Riggs BL. Bone formation rate in older normal women: concurrent assessment with bone histomorphometry, calcium kinetics, and biochemical markers. J Clin Endocrinol Metab 1988; 67: 741–48.
82Whyte PM, Bergfeld MA, Murphy WA, Avioli LV, Teitelbaum SL. Post-menopausal osteoporosis. A heterogenous disorder as assessed by histomorphometric analysis of iliac crest bone from untreated patients. Am J Med 1982; 72: 192202.
83Meunier PJ, Courpron P, Edouard C et al. Bone histomorphometry in osteoporotic states. In: Barzel US ed. Osteoporosis, Volume II. New York: Grune and Stratton, 1979: 2747.
84Eriksen EF, Hodgson SF, Eastell R, Cedel SL, O'Fallon WM, Riggs BL. Cancellous bone remodelling in type I (postmenopausal) osteoporosis: quantitative assessment of rates of formation, resorption and bone loss at tissue and cellular levels. J Bone Miner Res 1990; 5: 311–19.
85Darby AJ, Meunier PJ. Mean wall thickness and formation periods of trabecular bone packets in idiopathic osteoporosis. Calcif Tissue Int 1981; 33: 199204.
86Garcia-Carasco M, De Vernejoul MC, Sterkers Y, Morieux C, Kuntz D, Miravet L. Decreased bone formation in osteoporotic patients compared to age-matched controls. Calcif Tissue Int 1989; 44: 173–75.
87Arlot M, Edouard, Meunier PJ, Neer RM, Reeve J. Impaired osteoblast function in osteoporosis: comparison between calcium balance and dynamic histomorphometry. Br Med J 1984; 289: 517–20.
88Steiniche T, Hasling C, Charles P, Eriksen EF, Mosekilde L, Melsen F. A randomised study on the effects of oestrogen-gestagen or high dose oral calcium on trabecular bone remodelling in postmenopausal osteoporosis. Bone 1989; 10: 313–20.
89Eriksen EF, Colvard DS, Berg NJ et al. Evidence of estrogen receptors in normal human osteoblast-like cells. Science 1988; 241: 8486.
90Komm BS, Terpening CM, Benz DJ et al. Estrogen binding, receptor mRNA and biologic response in osteoblast-like osteosarcoma cells. Science 1988; 241: 8185.
91Pacifici R, Brown C, Puscheck E et al. Effect of surgical menopause and estrogen replacement on cytokine release from human blood mononuclear cells. Proc Natl Acad Sci USA 1991; 88: 5134–38.
92Ralston SH, Russell RGG, Gowen M. Estrogen inhibits release of tumour necrosis factor from peripheral blood mononuclear cells in postmenopausal women. J Bone Miner Res 1990; 5: 983–88.
93Jilka RL, Hangoc G, Girasole G et al. Increased osteoclast development after estrogen loss: mediation by interleukin-6. Science 1992; 257: 8891.
94Gray TK, Mohan S, Linkhart TA, Baylink DJ. Estradiol stimulates in vitro the secretion of insulin-like growth factors by the clonal osteoblastic cell-line, UMR 106. Biochem Biophys Res Commun 1989; 158: 407–12.
95Ernst M, Heath JK, Rodan GA. Estradiol effects on proliferation, messenger ribonucleic acid for collagen and insulin-like growth factor-1, and parathyroid hormone-stimulating adenylate cyclase activity in osteoblastic cells from calvariae and long bones. Endocrinology 1989; 125: 825–33.
96Compston JE, Mellish RWE, Croucher PI, Newcombe R, Garrahan NJ. Structural mechanisms of trabecular bone loss in man. Bone Miner 1989; 6: 339–50.
97Parfitt AM, Mathews CHE, Villanueva AR, Kleerekoper M, Frame B, Rao DS. Relationship between surface, volume and thickness of iliac trabecular bone in ageing and in osteoporosis. J Clin Invest 1983; 72: 1396–409.
98Mellish RWE, Garrahan NJ, Compston JE. Age-related changes in trabecular width and spacing in human iliac crest biopsies. Bone Miner 1989; 6: 331–38.
99Croucher PI, Garrahan NJ, Compston JE. Structural mechanisms of trabecular bone loss in primary osteoporosis: specific disease mechanism or early ageing? Bone Miner 1994; 25: 111–21.
100Aitken JM. Relationship between mortality after femoral neck fracture and osteoporosis. In: Christiansen C, Johansen JS, Riis BJ eds. Osteoporosis 1987 Copenhagen: Osteopress ApS, 1987; 4548.
101Browner WS, Seely DG, Vogt TM, Cummings SR. Non-trauma mortality in elderly women with low bone mineral density. Lancet 1991; 338: 355–58.
102Parvizi ST, Minne HW, Bauss F, Ziegler R. Antioestrogens treatment produces loss of bone mass as a side-effect in the rat. Acta Endocrinol (Copenh) 1985; 108: 168–71.
103Turner RT, Wakley GK, Hannon KS, Bell NH. Tamoxifen prevents the skeletal effects of ovarian hormone deficiency in rats. J Bone Miner Res 1987; 5: 449–56.
104Gotfredson A, Christiansen C, Palshof T. The effect of tamoxifen on bone mineral content in premenopausal women with breast cancer. Cancer 1984; 53: 853–57.
105Love RR, Mazess RB, Barden HS et al. Effects of tamoxifen on bone mineral density in postmenopausl women with breast cancer. N Engl J Med 1992; 326: 852–56.
106Ward RL, Morgan G, Dalley D, Kelly PJ. Tamoxifen reduces bone turnover and prevents lumbar spine and proximal femoral bone loss in early postmenopausal women. Bone Miner 1993; 22: 8794.
107Neal AJ, Evans K, Hoskin PJ. Does long-term administration of tamoxifen affect bone mineral density? Eur J Cancer 1993; 29A: 1971–73.
108Wright CDP, Mansell RE, Gazet J-C, Compston JE. Effect of long term tamoxifen treatment on bone turnover in women with breast cancer. Br Med J 1993; 306: 429–30.
109Wright CDP, Garrahan NJ, Stanton M, Gazet J-C, Mansell RE, Compston JE. Effect of long-term tamoxifen therapy on cancellous bone remodelling and structure in women with breast cancer. J Bone Miner Res 1994; 9: 153–59.
110Johansen JS, Riis BJ, Hassager C, Moen M, Jacobson J, Christiansen C. The effect of a gonadotrophin-releasing hormone agonist (naferelin) on bone metabolism. J Clin Endocrinol Metab 1988; 67: 701706.
111Dawood MY, Lewis V, Ramos J. Cortical and trabecular bone mineral content in women with endometriosis: effect of gonadotrophin-releasing hormone agonist and danazol. Fertil Steril 1989; 52: 2126.
112Jacobson JB. Effects of naferelin on bone density. Am J Obstet Gynecol 1990; 162: 589–92.
113Whitehouse RW, Adams JE, Bancroft K, Vaughan-Williams CA, Elstein M. The effects of naferelin and danazol on vertebral trabecular bone mass in patients with endometriosis. Clin Endocrinol 1990; 33: 365–73.
114Rico H, Arnanz F, Revilla M et al. Total and regional bone mineral content in women treated with GnRH agonists. Calcif Tissue Int 1993; 52: 354–57.
115Compston JE, Yamaguchi K, Croucher PI, Garrahan NJ, Lindsay PC, Shaw RW. The effects of gonadotrophin-releasing hormone agonists on iliac crest cancellous bone structure in women with endometriosis. Bone 1994 (in press).
116Riis BJ, Christiansen C, Johansen JS, Jacobson J. Is it possible to prevent bone loss in young women treated with luteinizing hormone-releasing hormone agonists. J Clin Endocrinol Metab 1990; 70: 920–24.
117Eldred JM, Haynes PJ, Thomas EJ. A randomised double-blind controlled trial of the effects on bone metabolism of the combination of naferelin acetate and norethisterone. Clin Endocrinol (Oxf) 1992; 37: 354–59.
118Surrey ES, Judd HL. Reduction of vasomotor symptoms and bone mineral density loss with combined norethindrone and long-acting gonadotrophin-releasing hormone agonist therapy of symptomatic endometriosis: a prospective randomised trial. J Clin Endocrinol Metab 1992; 75: 558–63.
119Lindsay R, Hart DM, Kraszewski A. Prospective double-blind trial of synthetic steroid (Org OD 14) for preventing postmenopausal osteoporosis. Br Med J 1980; 280: 1207–209.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Reproductive Medicine Review
  • ISSN: 0962-2799
  • EISSN: 1469-9028
  • URL: /core/journals/reproductive-medicine-review
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 4 *
Loading metrics...

Abstract views

Total abstract views: 68 *
Loading metrics...

* Views captured on Cambridge Core between September 2016 - 23rd October 2017. This data will be updated every 24 hours.